Group 1 - The core viewpoint of the article highlights the positive market response to Fuhong Hanlin's recent clinical developments, with the stock price increasing over 8% during trading and closing at 77.95 HKD, reflecting a 5.34% gain [1] - Fuhong Hanlin has completed the first patient dosing in the U.S. for its HLX43, a PD-L1 antibody-drug conjugate, in a Phase II clinical trial for advanced non-small cell lung cancer (NSCLC) [1] - The company is evolving into an innovative biopharmaceutical firm centered around HLX43, as indicated by the cash flow generated from its biosimilars in China and globally [1] Group 2 - Fuhong Hanlin has had 10 lung cancer studies accepted for presentation at the 2025 World Conference on Lung Cancer (WCLC), focusing on three core innovative drugs: anti-PD-1 monoclonal antibody H drug, anti-EGFR monoclonal antibody HLX07, and the PD-L1 ADC HLX43 [1] - Citigroup anticipates that Fuhong Hanlin will present the latest data on HLX43 at WCLC, which could further demonstrate its potential in treating NSCLC [1] - If HLX43 maintains an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in larger samples, the data will be highly persuasive [1]
港股异动 | 复宏汉霖(02696)盘中涨超8% HLX43完成美国首例患者给药 旗下三款核心产品将亮相WCLC